Healthcare AI Learning
Course overview

Module 9 · 95 min

Regulation & Governance

Know Which Rules Apply — and Turn Them into Decisions. Which rules actually apply to a proposed AI use, and how to turn that into decisions: AI Act classification and the current timeline, MDR/IVDR and software as a medical device, GDPR, EHDS, and an approval path with named owners rather than a committee maze.

Lesson progress
0 / 8 steps
Not started
Learning objectives
  • Treat regulation as a routing question — what is the intended use, who is the actor, what data is involved — rather than as a single yes/no gate applied after a system has been chosen.
  • Recognise that one system can sit under several regimes at once, and that AI Act, medical-device, data-protection and national supervisory requirements apply in parallel rather than in sequence.
  • Place a proposed use into the right AI Act category — prohibited practice, transparency obligation, Annex III high-risk, high-risk through the regulated-product route, or none of these — and state which facts the answer depends on.
  • Use the current 2026 AI Act timeline, including the changed application dates for high-risk systems, instead of pre-2026 summaries that are now wrong.
  • Distinguish the organisation's role as deployer from the provider role it can acquire by developing, rebranding or substantially modifying a system.
  • Judge when software has a medical intended purpose and therefore a device route under MDR or IVDR, and understand what a change or new version can trigger.
  • Separate the legal risk classification of an AI system from its clinical risk, and explain why a low legal classification is not a safety argument.
  • Make the two data-protection decisions that most often go wrong: the Article 6 lawful basis together with the Article 9 condition, and the controller versus processor role — including why consent is frequently not the right basis in healthcare.
  • Explain primary and secondary use under EHDS, the phased dates, and what an organisation can sensibly prepare now.
  • Assemble a reusable regulatory and governance passport for any AI use case, and map each decision to a named owner and an evidence artefact.
  • Design an approval path that is fast and predictable rather than a committee maze, and distinguish 'proceed', 'proceed with conditions' and 'clarify a fact first'.

Stated as of 28 August 2026

Regulatory content in this module is stated as of 28 August 2026 and reflects the AI Act timeline as amended by the 2026 digital omnibus package. Timetables, national implementation and guidance change; verify the current position against the primary sources in the references before any real decision. Nothing here is legal advice.

The AI Act: classify the use, not the technology

The AI Act is a product-safety style regulation for artificial intelligence, and its central move is to regulate uses rather than technologies. The same underlying model can be unregulated in one deployment, subject to transparency duties in a second and high-risk in a third. This is why 'is our large language model compliant?' is not a well-formed question: compliance attaches to what you do with it.

It entered into force on 1 August 2024 and became generally applicable on 2 August 2026, with obligations switched on in stages. The staging matters in practice, because a summary written in 2024 or 2025 will give you the wrong dates for the high-risk categories.

Two more distinctions do most of the work for a healthcare leader. The first is between categories: a use is either a prohibited practice, or carries transparency obligations, or is high-risk, or is none of those — and 'none of those' is the correct answer far more often than the current discourse suggests. The second is between roles: providers carry the bulk of the obligations, deployers carry a narrower and more operational set.

The timeline, as it stands in August 2026

  1. 1 August 2024 · Entry into force

    The Regulation is law; the obligations begin to apply in stages from this point.

  2. 2 February 2025 · Prohibited practices and AI literacy

    The bans in Article 5 apply, together with the obligation on providers and deployers to ensure a sufficient level of AI literacy among staff operating AI systems.

  3. 2 August 2025 · General-purpose AI and governance

    Obligations for general-purpose AI models, together with the governance and penalties architecture, begin to apply.

  4. 2 August 2026 · General application

    The Regulation applies generally, including the Article 50 transparency obligations and the enforcement powers of the national authorities.

  5. 2 December 2027 · Annex III high-risk systems (changed date)

    Following the 2026 digital omnibus amendments, obligations for high-risk systems listed in Annex III apply from this date rather than from August 2026. Older summaries state the earlier date and are now wrong.

  6. 2 August 2028 · High-risk AI in regulated products (changed date)

    Obligations for high-risk AI that is a safety component of, or a product covered by, the Annex I harmonisation legislation — the route most relevant to medical devices — apply from this date under the amended timeline.

Teaching guidance, not legal advice: a later application date is not permission to design without regard to the requirements. Systems procured in 2026 will still be running when the high-risk obligations bite, and retrofitting logging, documentation and human-oversight design into a live deployment costs considerably more than specifying it in the contract now. Treat the dates as a planning horizon rather than a holiday.

The categories

Prohibited practices

A small, specific list of uses banned outright since February 2025 — including certain manipulative techniques, social scoring, and inferring emotions in the workplace or in education, subject to defined exceptions such as medical or safety purposes.

In healthcare: Rarely relevant to clinical software, and occasionally very relevant to workforce and facilities proposals. Emotion inference on staff is the example that most often surfaces in a healthcare organisation, usually attached to a wellbeing or productivity pitch.

Transparency obligations

Duties that attach to certain uses regardless of risk classification: telling people they are interacting with an AI system unless it is obvious, and marking synthetic or manipulated content.

In healthcare: Directly relevant to patient-facing chatbots, automated messaging and synthetic media in patient information. Applies from 2 August 2026 and is usually straightforward to satisfy if it is designed in rather than bolted on.

High-risk — Annex III

Listed use cases in defined areas such as employment and worker management, education, essential public and private services — including emergency services and, under point 5(d), AI systems used for triage of patients in emergency healthcare — and certain uses by public authorities.

In healthcare: Recruitment screening, workforce allocation and some access-to-service decisions can land here. Most of this route is unrelated to whether the tool is clinical — but Annex III point 5(d) specifically covers AI systems used for emergency healthcare patient triage.

High-risk — regulated products (Article 6(1))

Two conditions must both be met: the AI system is a safety component of, or is itself, a product covered by the Annex I harmonisation legislation; and that product is subject to third-party conformity assessment under that legislation.

In healthcare: This is the route by which many medical-device AI systems become high-risk — but only when the third-party assessment condition is also met. A self-certified class I device does not satisfy the second condition through that route.

None of these

A system that is not prohibited, not in Annex III, not high-risk through the product route, and not caught by a transparency duty.

In healthcare: Common, and worth saying out loud. Many operational and administrative tools sit here. General AI-literacy duties and every other regime — data protection, professional standards, clinical safety — still apply.

Provider and deployer

Provider

The actor that develops an AI system, or has one developed, and places it on the market or puts it into service under its own name or trademark.

Carries: The bulk of the obligations for high-risk systems: risk management, data governance, technical documentation, logging, transparency to deployers, human-oversight design, accuracy and robustness, quality management and conformity assessment.

Deployer

The actor using an AI system under its own authority in a professional capacity. Most healthcare organisations, most of the time.

Carries: A narrower, operational set: use the system in accordance with the instructions, assign competent human oversight with the authority to act, ensure input data is relevant for the intended purpose where you control it, keep logs where applicable, inform affected workers and people where required, and cooperate with authorities.

Becoming a provider without meaning to

An organisation that puts its own name on a system, changes its intended purpose, or substantially modifies a high-risk system.

Carries: Provider obligations for the system as changed. Teaching guidance: treat 'we fine-tuned it on our own data and rebranded it' as a governance trigger requiring specialist advice, not as a configuration detail.

Optional depth: five things people get wrong about the AI Act in healthcareCommon misreadings, and the accurate position on each. Useful before a governance meeting; not assessed separately.

All healthcare AI is high-risk under the AI Act.

It is not. High-risk status arrives either through an Annex III listing or through Article 6(1), which requires both a product covered by Annex I harmonisation legislation and third-party conformity assessment. Plenty of healthcare AI meets neither test, and plenty of non-clinical healthcare AI — recruitment screening, for instance — is high-risk for reasons unrelated to patients.

If it is a CE-marked medical device, it is automatically high-risk AI.

Only where both Article 6(1) conditions hold. The third-party conformity assessment condition is what does the work, which is why device class matters to the analysis.

The AI Act replaces MDR for AI-based devices.

It does not. The two apply in parallel and complementarily, and the Commission and MDCG have published joint guidance precisely because organisations kept assuming one displaced the other.

As a hospital we are only ever a deployer.

Usually, but not inherently. Developing a system yourself, placing one on the market under your own name, or substantially modifying a system can bring provider obligations with it. The role follows the activity.

Low legal risk classification means low clinical risk.

These are different scales. A tool outside every high-risk category can still cause harm through a bad workflow, and a high-risk classification is a statement about legal obligations rather than a prediction of patient harm. Keep the two assessments separate and do both.

Classify these six

Six fictional proposals at Meadowbrook Health Group. Place each into the AI Act category that best fits the facts as stated. The point is the reasoning: in every case, note which single fact would change your answer if it turned out to be different.

0 / 6 correct · 0 of 6 classified

1. Wellbeing dashboard inferring staff emotional state

A supplier offers a tool that analyses tone of voice in recorded handover calls to infer stress and fatigue in ward staff, presenting an anonymised team-level 'wellbeing index' to line managers. It is pitched as a workforce retention aid, not as a clinical or occupational-health instrument, and no medical or safety purpose is claimed for it.

2. Shortlisting tool for nursing recruitment

HR proposes software that scores and ranks applications for nursing posts against the job description, producing a shortlist that recruiting managers review before interview. No patient data is involved and the tool has nothing to do with clinical care.

3. CT triage software, class IIa with notified-body certification

The imaging triage system described earlier: CE-marked under MDR as a class IIa device with a notified body involved in the conformity assessment, intended to prioritise studies with suspected time-critical findings on the reporting worklist.

4. Patient-facing information chatbot on the website

A conversational assistant on the public website answers questions about visiting hours, preparation for common procedures and how to contact a department. It is explicitly not intended to give clinical advice, and clinical questions are routed to a human contact route.

5. Theatre-list sequencing optimiser

An internal tool that proposes an order for elective theatre lists to reduce turnaround gaps, taking account of equipment and staffing constraints. A scheduling coordinator reviews and adjusts the proposal, which does not determine whether or when any individual patient receives treatment.

6. Sepsis alerting module, self-certified class I

A supplier offers an early-warning module for suspected sepsis, CE-marked as a class I medical device under a self-certification route with no notified body involved in the conformity assessment.

The pattern across the six is worth naming. The category never followed from how advanced the technology was; it followed from the intended purpose, the affected people and the conformity route. That is why classification is cheap when the intended purpose is written down precisely, and expensive when it is not.

Attempt all 6 items to continue — 0 done so far. Answers do not have to be correct.
Sources & evidence · 11 sources

This module cites primary legal, public or consensus guidance. Regulatory position stated as of 28 August 2026, reflecting the AI Act timeline as amended by the 2026 digital omnibus package; recheck primary sources before any real decision.

Content reviewed: September 2026. Publication dates of the individual sources are shown in each citation.

  • European Commission. Regulatory framework for AI — overview and application timeline. Digital Strategy, accessed 28 August 2026.

    The Commission's own overview of the AI Act's risk-based structure and staged application. Use it to confirm the current category definitions and dates. It is an explanatory overview, not the legal text, and it does not classify any individual product.

    Open source
  • European Commission. Enforcement of the AI Act — application dates and supervisory architecture (updated August 2026).

    The current statement of which obligations apply from which date, including the amended high-risk dates of 2 December 2027 for Annex III and 2 August 2028 for high-risk AI in regulated products. This page is the check to run before repeating any timeline written before 2026; it does not describe national implementation.

    Open source
  • Regulation (EU) 2024/1689 of the European Parliament and of the Council laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). OJ L, 12 July 2024.

    The legal text: definitions, Article 5 prohibitions, Article 6 high-risk classification and Annex III, Article 50 transparency obligations, and provider and deployer duties. Authoritative on what the obligations are; it does not tell you which category a specific product falls into, which is a factual analysis of intended purpose. Consolidated text as amended by Regulation (EU) 2026/1744 (in force 27 July 2026).

    Open source
  • Regulation (EU) 2017/745 on medical devices (MDR). Consolidated text. Annex VIII Rule 11.

    The primary source for software classification: Rule 11 places software providing information for diagnosis or therapeutic decisions generally in class IIa, higher where decisions may cause serious or irreversible harm, and classifies monitoring software separately. Educational summary only — not legal advice.

    Open source
  • European Commission, Joint Artificial Intelligence Board and Medical Device Coordination Group. MDCG 2025-6 / AIB 2025-1: FAQ on the interplay between the Medical Devices Regulations (MDR/IVDR) and the AI Act, June 2025.

    The official joint position on how MDR/IVDR and the AI Act apply simultaneously and complementarily, including how the Article 6(1) conditions interact with device conformity routes and how documentation obligations overlap. It is guidance on interpretation; it does not amend either Regulation.

    Open source
  • Regulation (EU) 2016/679 (General Data Protection Regulation). OJ L 119, 4 May 2016.

    The source for Article 6 lawful bases, the Article 9 regime for special-category data including health, controller and processor roles, purpose limitation and minimisation, Article 35 impact assessments and Article 22 on solely automated decisions. Determining which basis and condition apply to a specific processing operation is a factual and legal judgement for your DPO.

    Open source
  • Regulation (EU) 2025/327 on the European Health Data Space. OJ L, 5 March 2025.

    Establishes the primary-use and secondary-use frameworks, the phased application from 26 March 2027 with milestones in 2029 and 2031, and the health data access body architecture. It sets direction and dates; national implementation detail and the practical access processes are still developing.

    Open source
  • Autoriteit Persoonsgegevens. Toezicht op AI wordt concreet: sleutelrol voor de AP en de RDI, 20 April 2026.

    The Dutch data protection authority's account of the proposed national AI Act supervision architecture, with coordinating roles for the AP and RDI alongside sectoral supervisors. As of August 2026 this reflects a proposal and an implementation law still being finalised — treat the allocation as provisional rather than settled law.

    Open source
  • Autoriteit Persoonsgegevens. Aan de slag met de FRIA, 17 August 2026.

    Practical Dutch guidance on the fundamental rights impact assessment, including which deployers of Annex III high-risk systems it applies to and how it relates to the DPIA. The obligation is tied to the December 2027 application date for Annex III systems; the guidance is a practical aid, not an additional legal requirement.

    Open source
  • Inspectie Gezondheidszorg en Jeugd. Toetsingskader Digitale Zorg, 11 August 2026.

    The Dutch healthcare inspectorate's framework for assessing digital care, setting out the conditions it expects providers to meet when care is delivered with digital means — governance, competence, safety and evaluation. It concerns responsible digital care; it is not an AI-specific product classification system and does not determine device status or AI Act category.

    Open source
  • Inspectie Gezondheidszorg en Jeugd. EU-conformiteit van medische hulpmiddelen: verplichtingen bij aanschaf en gebruik.

    States the expectation that healthcare providers verify EU conformity when acquiring and first using a medical device, and that software can be a medical device depending on its medical intended purpose. It establishes a verification duty on the deploying organisation; it does not assess whether a given device performs well in your population.

    Open source

Applied practice: Regulatory Classification Lab

Route three proposed uses through intended purpose, the AI Act, medical-device law and GDPR — and see why the answers differ by use, not by technology.

Open lab

Capstone Board Pack

Add what you just learned to your own strategy document while it is fresh.

Open capstone